Injectable HIV treatment tested over five years in thousands of patients
NCT ID NCT07703748
First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time
Summary
This study follows over 3,300 people with HIV in Spain who switched from daily oral medication to a long-acting injectable combination of cabotegravir and rilpivirine. Researchers track how well the injections control the virus, how long patients stay on treatment, and any side effects over five years. The goal is to see if this convenient shot-based regimen works safely in real-world settings, including in older adults, women, and people with other health conditions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a long-acting injectable combination of cabotegravir and rilpivirine
- What this could lead to
- If successful, this study could confirm that long-acting injectable HIV treatment works well over many years in diverse patient groups, offering a convenient alternative to daily pills.
- What could go wrong
- This is an observational study, not a controlled trial, so results may be influenced by patient selection or real-world factors. Long-term safety and effectiveness are still being evaluated.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV-1 INFECTION IN ADULTS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hospital Universitario de Burgos
Burgos, Spain